Brief: GeNeuro, Karolinska Institutet’s ASC Update On Temelimab Neurodegeneration Prevention Study
14/09/2020 06:34
Sept 14 (Reuters) - Geneuro SA GNRO.PA :
* GENEURO AND THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC)
PRESENT
TEMELIMAB NEURODEGENERATION PREVENTION STUDY AT MSVIRTUAL2020
* LONG-TERM CLINICAL STUDY DATA HAS SHOWN THAT TEMELIMAB, GENEURO'S LEAD
COMPOUND
UNDER CLINICAL DEVELOPMENT, HAS A REMARKABLY CONSISTENT NEUROPROTECTIVE EFFECT
ON KEY MRI MEASURES LINKED TO MS DISEASE PROGRESSION
Source text for Eikon: ID:nBw66MpDba
Further company coverage: GNRO.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement